New Addition to Covered Stock: OPT (OPTHEA)
Opthea Limited (ASX:OPT), a late stage
biopharmaceutical company developing first-in-class novel biologic therapies to treat back-of-the eye
diseases namely wet AMD which is a leading cause of blindness in people aged >55 years and DME the leading cause of blindness
amongst diabetics. There are already existing treatment for these two leading causes of blindness via drugs Lucentis (Roche/Novartis) and
Eyelea (Regeneron / Bayer) in a market that generated $9.2B in 2017. Opthea's lead drug development candidate OPT-302 is designed to
add-on and accentuate these existing remedies, not compete by offering a novel and differentiated additional treatment to VEGF-C and VEGF-D while Lucentis and Eyelea only addresses VEGF-A- VEGF represent vascular endothelial growth factor responsible for vessel growth and vascular leakages. The potential market opportunity presented by OPT-302 is estimated to be in excess of $10B.
OPT is now trading at just $150m market cap and has received positive safety review from its Phase 2b clinical trials.
COVERAGE DATE STOCKS PRICE ON COVERAGE DATE PRICE @ARVO GAIN% 17/10 OPT $ 0.600 $ 0.600 0.0% 15/10 PPS $ 0.915 $ 0.885 -3.3% 15/10 SVA $ 0.033 $ 0.031 -6.1% 15/10 APX $ 12.010 $ 11.860 -1.2% 15/10 PME $ 9.990 $ 10.160 1.7% 11/10-close PPS $ 0.925 $ 0.970 4.9% 11/10-close BBUS $ 4.750 $ 4.810 1.3% 3/10 BIT $ 0.140 $ 0.275 96.4% 26/9-close CXL $ 0.735 $ 0.800 8.8% 20/9-close 4DS $ 0.064 $ 0.066 3.1% 3/9 NST $ 8.140 $ 8.965 10.1% 29/8-close SVA $ 0.037 $ 0.035 -5.4% 20/8-close NGI $ 5.810 $ 5.160 -11.2% 8/8-close SFC $ 15.050 $ 16.470 9.4% 6/8-close CGL $ 7.080 $ 7.930 12.0% 31/7-close MYE $ 1.180 $ 1.435 21.6% 30/7-close MP1 $ 4.370 $ 3.990 -8.7% 26/7-close SKF $ 0.150 $ 0.200 33.3% 24/7-close ZEN $ 1.060 $ 0.785 -25.9% 23/7-close CXL $ 0.630 $ 0.830 31.7% 17/7 COE $ 0.445 $ 0.470 5.6% 13/7-close SHL $ 26.500 $ 25.360 -4.3% 29/6 BYE $ 0.340 $ 0.285 -16.2% 28/6-close ATC $ 0.195 $ 0.140 -28.2% 18/6-close A2M $ 10.780 $ 11.490 6.6% 18/6-close CGC $ 8.750 $ 7.240 -17.3% 14/6-close NZK $ 2.240 $ 2.480 10.7% 4/6-close BUB $ 0.830 $ 0.625 -24.7% 15/5-close SW1 $ 0.410 $ 0.380 -7.3% 14/5-close RHC $ 65.420 $ 55.250 -15.5% 9/5-close FYI $ 0.145 $ 0.115 -20.7% 3/5-close 4DS $ 0.057 $ 0.100 75.4% 2/5-close PME $ 8.150 $ 10.860 33.3% 1/5-close TTT $ 1.540 $ 1.525 -1.0% 30/4-close CTD $ 24.880 $ 33.540 34.8% 18/4-close CLV $ 1.030 $ 1.575 52.9% 18/4-close VIV $ 0.054 $ 0.043 -20.4% 11/4-close APX $ 8.820 $ 15.010 70.2% 11/4-close BHP $ 29.440 $ 32.385 10.0% 11/4-close PPS $ 0.595 $ 1.135 90.8% 11/4-close PTB $ 0.545 $ 0.625 14.7% Return @ 10.83% assuming @ $1k even per stock
Opthea’s lead drug development
candidate OPT‑302, blocks the
activity of two members of this
family, namely VEGF-C and VEGF-D.
Approved therapies for wet AMD and
DME include Lucentis® (ranibizumab)
and Eylea® (aflibercept). These
agents block the activity of VEGF-A,
but not VEGF-C or VEGF-D.
